Bristol Myers Squibb
About Bristol Myers Squibb
Bristol Myers Squibb engages in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of pharmaceuticals.
Investment focus
Sectors
Portfolio (13 in our database)
OwkinOwkin is an AI precision medicine company with a vision to find the right drug for every patient.Series B · $334M raisedVedanta BiosciencesVedanta Biosciences is a developer of immunotherapies designed to treat immune-mediated and infectious diseases.Series D · $302M raisedMetagenomiMetagenomi is using the power of metagenomics and machine learning to discover novel genome editing systems.Series B · $277M raisedPersonal Genome DiagnosticsPersonal Genome Diagnostics develops a patient-specific analysis of the cancer genome by using advanced tools and technologies.Acquired · $245M raisedRibon TherapeuticsRibon Therapeutics is a biotechnology company focused on the development of therapeutics treatments targeting stress support pathways.Series C · $184M raisedBe BiopharmaBe Biopharma is developing B ceaBe Biopharma is a biotech research company that develops a class of B cells as medicines.lls as medicines.Series B · $182M raisedObsidian TherapeuticsObsidian Therapeutics is a developer of a next-generation cell and gene therapies created to extend adoptive immunotherapy.Series B · $165M raisedHiberCellHiberCell is a biotechnology company developing treatments to prevent cancer relapse and metastasis.Series B · $158M raisedOctant BioOctant Bio is a developer of synthetic technology used to improve health and treat disease.Series B · $115M raisedOrna TherapeuticsOrna Therapeutics is a biotechnology company that specializes in fully engineered circular RNA (oRNA) therapeutics to treat various diseasesSeries A · $100M raisedClade TherapeuticsClade Therapeutics discovers and delivers next-generation cell medicines to improve the lives of patients.Series A · $87M raisedSapience TherapeuticsSapience Therapeutics is a preclinical-stage biotechnology company focused on advancing novel therapeutics for major unmet medical needsSeries B · $72M raisedTransition BioTransition Bio provides condensate technology for drug discovery and diagnostics.Series A · $50M raised